NLRP3 inhib 
Welcome,         Profile    Billing    Logout  
 7 Companies  6 Products   6 Products   29 Diseases   11 Trials   763 News 


«12...7891011121314151617...134135»
  • ||||||||||  Journal:  Sting mutation attenuates acetaminophen-induced acute liver injury by limiting NLRP3 activation. (Pubmed Central) -  Dec 27, 2023   
    Besides, pretreatment of MCC950 in C57 mice resulted in changes of immune cells infiltration in the liver similar to Sting mice. Our study revealed that STING played a crucial role in APAP-induced acute liver injury, possibly by maintaining liver immune cells homeostasis and inhibiting NLRP3 inflammasome activation, suggesting that inhibiting STING-NLRP3 pathway might be a potential therapeutic strategy for acute liver injury.
  • ||||||||||  Kineret (anakinra) / SOBI
    Journal:  NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy. (Pubmed Central) -  Dec 24, 2023   
    Treatment of a CMML patient with a KRAS mutation using the IL-1 receptor blocker anakinra inhibits NLRP3 inflammasome activation, reduces monocyte count, and improves the patient's clinical status, enabling a stem cell transplant. This reveals a basal inflammasome activation in RAS-mutated CMML patients and suggests potential therapeutic applications of NLRP3 and IL-1 blockers.
  • ||||||||||  Journal:  Curculigoside inhibits osteoarthritis via the regulation of NLRP3 pathway. (Pubmed Central) -  Dec 23, 2023   
    The findings demonstrated that HDAX-containing serum can inhibit the pyroptosis-mediated by NLRP3 and protect PC12 cells from the cognitive dysfunction induced by high glucose. Furthermore, the expression of NLRP3, NF-?B and PKR was downregulated after curculigoside administration.
  • ||||||||||  Journal:  Characterization of Inflammasomes and Their Regulation in the Red Fox. (Pubmed Central) -  Dec 23, 2023   
    These findings suggest that NLRP3 may have a common role in dsDNA- and flagellin-mediated inflammasome activation in the red fox. It implies that this fox inflammasome biology can be applied to the treatment of inflammasome-mediated diseases in the red fox.
  • ||||||||||  doxycycline / Generic mfg.
    Journal:  Ribosome-targeting antibiotic control NLRP3-mediated inflammation by inhibiting mitochondrial DNA synthesis. (Pubmed Central) -  Dec 22, 2023   
    In addition, in vivo results indicated that doxycycline mitigated NLRP3 inflammasome-dependent inflammation, including lipopolysaccharide-induced systemic inflammation and endometritis. Taken together, the results unveil the antibiotics targeting the mitoribosome have the ability to mitigate NLRP3 inflammasome activation by inhibiting mitochondrial translation and mtDNA synthesis thus opening up new possibilities for the treatment of NLRP3-related diseases.
  • ||||||||||  Journal:  Naringin alleviates pneumonia caused by Klebsiella pneumoniae infection by suppressing NLRP3 inflammasome. (Pubmed Central) -  Dec 19, 2023   
    These results indicated that NAR could protect against Kpn-induced pneumonia by inhibiting the overactivation of the NLRP3 inflammasome signaling pathway. The results of this study confirm the efficacy of NAR in treating bacterial pneumonia, refine the mechanism of action of NAR, and provide a theoretical basis for the research and development of NAR as an anti-inflammatory adjuvant.
  • ||||||||||  Journal:  Selective inhibition of the NLRP3 inflammasome protects against acute ethanol-induced cardiotoxicity in an FBXL2-dependent manner. (Pubmed Central) -  Dec 19, 2023   
    Our data further suggest that FBXL2, an E3 ubiquitin ligase associated with mitochondrial homeostasis and mitophagy, is destabilized due to proteasomal degradation of caspase-1 by ethanol-induced hyperactivation of NLRP3-caspase-1 inflammasome signaling, resulting in mitochondrial injury and apoptosis. These findings denote a role for NLRP3 inflammasome in acute ethanol exposure-induced cardiotoxicity in an FBXL2-dependent manner and the therapeutic promise of targeting NLRP3 inflammasome for acute ethanol cardiotoxicity.
  • ||||||||||  Review, Journal:  NLRP3-Induced NETosis: A Potential Therapeutic Target for Ischemic Thrombotic Diseases? (Pubmed Central) -  Dec 17, 2023   
    Recent investigations also implicate a role for the nucleotide-binding oligomerization domain (NOD)-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome as a mediator of NETosis and thrombosis, suggesting that NLRP3 inhibition may also hold potential for mitigating thrombotic events. Therefore, future preclinical and clinical studies aimed at identifying and validating NLRP3 inhibition as a novel therapeutic intervention for thrombotic disorders are imperative.
  • ||||||||||  Journal:  Stefin B Inhibits NLRP3 Inflammasome Activation via AMPK/mTOR Signalling. (Pubmed Central) -  Dec 17, 2023   
    Our study showed that increased stefin B expression downregulated mitochondrial ROS generation and increased autophagy. The present work contributes to a better understanding of the role of stefin B in regulation of autophagy and inflammasome activation in macrophages and could help to develop new treatments.
  • ||||||||||  Journal:  A detailed molecular network map and model of the NLRP3 inflammasome. (Pubmed Central) -  Dec 17, 2023   
    While the exact mechanisms of NLRP3 activation remains elusive, the literature indicates that the different stimuli converge on a single activation mechanism that is additionally controlled by distinct (positive or negative) priming and licensing events through covalent modifications of the NLRP3 molecule. Taken together, we present a compilation of the literature knowledge on the molecular mechanisms on NLRP3 activation, a detailed mechanistic model of NLRP3 activation, and explore the convergence of diverse NLRP3 activation stimuli into a single input mechanism.
  • ||||||||||  Review, Journal:  Crosstalk of NLRP3 inflammasome and noncoding RNAs in cardiomyopathies. (Pubmed Central) -  Dec 17, 2023   
    In addition, their role in different cardiomyopathies was indicated in recent studies. This review article provides a summary of recent advancements focusing on the function of the NLRP3 inflammasome in common CVDs, especially cardiomyopathy, while also discussing the therapeutic potential of inhibiting the NLRP3 inflammasome regulated by ncRNAs.
  • ||||||||||  Journal:  Brevilin A ameliorates sepsis-induced cardiomyopathy through inhibiting NLRP3 inflammation. (Pubmed Central) -  Dec 15, 2023   
    When different concentrations of BA were used in sepsis cardiomyopathy in vivo and in vitro, the above-mentioned myocardial inflammation and injury factors were suppressed to varying degrees, cell viability increased, cardiac function improved, and the survival rate of rats also increased. BA ameliorated sepsis cardiomyopathy by inhibiting NF-?B/NLRP3 inflammation activation.
  • ||||||||||  Preclinical, Journal:  Caspase-1 Responsive Nanoreporter for In Vivo Monitoring of Inflammasome Immunotherapy. (Pubmed Central) -  Dec 11, 2023   
    Our results exhibited the nanoreporter's ability to penetrate inflammatory tissues and detect inflammasome activation early and in real-time for multiple days while alleviating inflammation in the groups coencapsulating imaging reporter and inflammasome inhibitor. Overall, the developed liposomal nanoreporter platform enables spatiotemporal delivery of imaging probe and inhibitor, captures early and sustained inflammasome detection, and induces inflammasome amelioration, thus establishing a novel tool for the real-time monitoring and treatment of inflammasome-mediated disease with high potential for clinical application.
  • ||||||||||  Journal:  Lipin-2 regulates the antiviral and anti-inflammatory responses to interferon. (Pubmed Central) -  Dec 11, 2023   
    Finally, analyses of databases from COVID-19 patients show that LPIN2 expression levels negatively correlate with the severity of the disease. Overall, these results uncover novel regulatory mechanisms of the IFN response driven by lipin-2 and open new perspectives for the future management of patients with LPIN2 mutations.
  • ||||||||||  Journal, Metastases:  Euphorbia factor (Pubmed Central) -  Dec 8, 2023   
    Meanwhile, EFL2 dose?dependently downregulated the mRNA and protein expression of NLRP3 and related molecules in the model, and overexpression of NLRP3 abolished these beneficial effects of EFL2. Taken together, the present experimental data suggested that EFL2 has a significant inhibitory effect on ascites of breast cancer liver metastasis in
  • ||||||||||  Review, Journal:  Protein-protein interactions and related inhibitors involved in the NLRP3 inflammasome pathway. (Pubmed Central) -  Dec 5, 2023   
    This review focuses on summarizing PPIs within the NLRP3 inflammasome activation pathway and small molecule inhibitors capable of interfering with PPIs to counteract the NLRP3 overactivation. Small molecule NLRP3 inhibitors have been gained significant attention owing to their remarkable efficacy, excellent safety profiles, and unique mechanisms of action.
  • ||||||||||  Review, Journal:  NLRP3 inhibitors: Unleashing their therapeutic potential against inflammatory diseases. (Pubmed Central) -  Dec 4, 2023   
    Hence, the application of NLRP3 inhibitors against inflammatory disease has not yet been understood and most of the developed inhibitors are unsuccessful in clinical trials. The processes behind the NLRP3 complex, priming, and activation are the main emphasis of this review, which also covers therapeutical inhibitors of the NLRP3 inflammasome and potential therapeutic strategies for directing the NLRP3 inflammasome towards clinical development.
  • ||||||||||  Kineret (anakinra) / SOBI
    Journal:  Hypertonic saline induces inflammation in human macrophages through the NLRP1 inflammasome. (Pubmed Central) -  Dec 4, 2023   
    Treatment with the recombinant IL-1 receptor antagonist anakinra or the NLRP3 inhibitor MCC950 did not affect NaCl-mediated inflammasome assembly...Data from this study suggest that 3% NaCl-induced inflammatory responses in human macrophages depend on NLRP1 and inflammasome assembly. Targeting inflammation in addition to inhalation with hypertonic saline may benefit patients with inflammatory airway disease.
  • ||||||||||  Journal, IO biomarker:  Muscone ameliorates myocardial ischemia?reperfusion injury by promoting myocardial glycolysis. (Pubmed Central) -  Dec 4, 2023   
    Chromatin immunoprecipitation assays showed that muscone treatment increased the expression level of H3K4me3 in the PKM2 promoter region and inhibited the levels of H3K27me3 and H2AK119Ub in the PKM2 promoter region. Muscone promoted myocardial glycolysis and inhibited NLRP3 pathway activation to improve myocardial ischemia?reperfusion injury.
  • ||||||||||  Journal:  Egg Yolk Lipids Alleviated Dextran Sulfate Sodium-Induced Colitis by Inhibiting NLRP3 Inflammasome and Regulating Gut Microbiota. (Pubmed Central) -  Dec 1, 2023   
    Moreover, the study also finds that egg yolk lipids reverse gut microbiota dysbiosis referring to increased relative abundance of Bacteroides acidifaciens and decrease relative abundance of Akkermansia muciniphila, as well as increased short chain fatty acids concentration in the gut. Together, the study elucidates the anti-colitis effect of egg yolk lipids and provides positive evidences for egg yolk lipids involving in dietary strategy and IBD therapy.
  • ||||||||||  Journal:  L-ergothioneine reduces mitochondrial-driven NLRP3 activation in gestational diabetes mellitus. (Pubmed Central) -  Nov 30, 2023   
    Furthermore, this increase may be initiated by elevated production of mitochondrial superoxide by macrophage subpopulations and orchestrated by the NLRP3 inflammasome. The mitochondrial antioxidant, L-ergothioneine, ameliorates NLRP3-induced placental inflammation in GDM, identifying a potential therapeutic role.